By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' ...

CVS Health (NYSE:CVS), one of the leading health insurers in the U.S. and owner of the Pharmacy Benefit Manager Caremark, ...

Investing.com -- CVS Health (NYSE: CVS) will not include Gilead Sciences (NASDAQ: GILD )’ new HIV prevention drug Yeztugo in its commercial plans for the time being, despite the medication’s proven ...

Dividend Growth: CVS has increased its dividend by 142% over the past decade, with a current forward yield of 4.64%. This significantly surpasses the S&P 500 average of 1.35%.

CVS to Exclusively Distribute Gilead Sciences's $1,000-Per-Pill Hepatitis C Treatment Published Jan 06, 2015 at 5:02 PM EST Updated Mar 12, 2016 at 9:16 AM EST ...

The battle for supremacy in one of the fastest-growing pharmaceutical markets intensified on Monday, with CVS Health Corp. saying it will make Gilead Sciences Inc.’s drugs Sovaldi and Harvoni ...

Gilead Sciences agreed to make its hepatitis C medicines the exclusive treatments for CVS Health customers, intensifying a drug-industry rivalry to win patients for the $1,000-a-day medicines.

CVS said the Gilead drugs would be exclusive on its standard commercial formulary, as well as those for exchanges created under the Affordable Care Act, Medicare Part D and Medicaid.

CVS Health announced Monday that it plans to make Gilead Sciences' hepatitis C drugs the exclusive option for most of its consumers starting Wednesday. January 06, 2015 • Tribune News Service ...

CVS Health Corp, one of the largest U.S. managers of drug benefits, said it would give preferred status to the hepatitis C treatments from Gilead Sciences and cover a new competing treatment from ...